Housatonic

Source: https://virtual.keystonesymposia.org/p/s/preparing-for-the-next-pandemic-the-emerging-infectious-disease-threat-10353 Downloaded July 17, 2024 - Some additional commentary added to the download Preparing for the Next Pandemic: The Emerging Infectious Disease Threat Streamed L January 28, 2019 NOTE - This video includes a panel discussion that was recorded during week of Oct 14-18, 2018, in Hong Kong Emerging infectious diseases are relatively little understood. Their periodic, unpredictable outbreaks can quickly transform into global pandemics, as was the case with SARS and avian influenza. They tend to be zoonotic (deriving from an animal source), infect thousands of people at a time, engender significant fear and panic, and have high mortality rates, which is frequently because the public infrastructure to diagnose, prevent and treat them is lacking. Newer examples of these diseases include MERS and Ebola, both of which are RNA viruses with the ability to mutate from one outbreak to the next, making them that much deadlier. This thought-provoking epanel broadcast will discuss a range of questions and challenges surrounding emerging infectious diseases, including: How do emerging infectious diseases differ from regular infectious diseases? What drives the emergence of these diseases? What are optimal ways to respond to emerging infectious disease outbreaks and is a new paradigm needed? How have societal changes such as international travel, livestock practices and social media changed the nature of pandemics, such as by amplifying disease transmission and sowing panic? Which newly emerging infectious diseases represent the greatest coming threats? How can we provide incentives for vaccinating animal carriers, some of whom don’t fall sick from the virus they are carrying? What is the role of big pharma in responding to these threats and who will fund the development of vaccines and other therapeutics? Following the panel discussion broadcast, audience members watching the live event will be able to participate in a live Q&A with the panelists. Questions can be submitted during the broadcast via Twitter or the chat room, or in advance when registering for the event. This epanel was filmed during the Keystone Symposia conference on “Framing the Response to Emerging Virus Infections” at the Lee Shau Kee Lecture Centre of The University of Hong Kong, October 14-18, 2018, and was made possible with funding from both The University of Hong Kong and the Croucher Foundation. Moderator : Andrew Bean, PhD / Commonwealth Scientific and Industrial Research Organization Panelists : Marion Koopmans, PhD / Erasmus Medical Centre John W. Lowenthal, PhD / Deakin University’s School of Medicine Malik Peiris, PhD / University of Hong Kong

https: //virtual.keystonesymposia.org/p/s/advancing-towards-a-general-solution-for-coronavirus-vaccines-poster-presentation-10295 Downloaded file ID: HV01AK "Advancing Towards a General Solution for Coronavirus Vaccines [POSTER PRESENTATION]" Speaker: Kizzmekia S. Corbett, PhD / NIH, NIAID, Vaccine Research Center Recorded During the Keystone Symposia Conference on: Framing the Response to Emerging Virus Infections (S2), Oct 14-18, 2018 | HKU, Hong Kong This Keystone Symposia Virtual Access was made possible by a grant from the Croucher Foundation and The University of Hong Kong.

Source : https://virtual.keystonesymposia.org/p/s/combined-use-of-live-attenuated-and-inactivated-influenza-vaccines-to-enhance-heterosubtypic-protection-10307 Downloaded file ID: HV01AG "Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection" Presented by: Li-Meng Yan, MD, PhD / The University of Hong Kong The limited protection of current commercial vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations. Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses. Recorded During the Keystone Symposia Conference on: Framing the Response to Emerging Virus Infections (S2), Oct 14-18, 2018 | HKU, Hong Kong This Keystone Symposia Virtual Access was made possible by a grant from the Croucher Foundation and The University of Hong Kong.

https://lagatapolitica.substack.com/p/no-sasha-susan-wojcicki-filed-a-police

Downloaded form : https://www.youtube.com/watch?v=BE_H7dTqJXU Downloaded on : July 2, 2024 HITS Asset ID HV01A2 "What We Know about the Coronavirus" Youtube account : Coalition for the Life Sciences 13,776 views Feb 28, 2020 Featuring Ralph Baric, PhD The University of North Carolina Wednesday, February 26, 2020 Cannon House Office Building Every day we hear a new report on the coronavirus. The reports range from the spread of the virus to the current mortality rates of victims of the virus. But what does science know about this virus? And is there hope for a treatment before the virus becomes even more deadly? Here is Dr. Ralph Baric, a leading epidemiologist, who has been working on finding a treatment for this virus. He discusses what we know and what we still don’t know about the coronavirus.